Algert Global LLC Buys 29,260 Shares of Celldex Therapeutics, Inc. $CLDX

Key Points

• Algert Global LLC increased its stake in Celldex Therapeutics by 28.0% during Q1, now owning 133,597 shares valued at approximately $2.4 million.
• The stock price of Celldex Therapeutics has seen a decline of 13.0%, currently trading at $20.89 with a market cap of $1.39 billion.
• Analysts have lowered their target prices for Celldex Therapeutics, with a new consensus rating of "Moderate Buy" and an average target price of $46.67.

Algert Global LLC raised its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 28.0% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 133,597 shares of the biopharmaceutical company's stock after acquiring an additional 29,260 shares during the period. Algert Global LLC owned approximately 0.20% of Celldex Therapeutics worth $2,425,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Vanguard Group Inc. raised its position in shares of Celldex Therapeutics by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 3,898,435 shares of the biopharmaceutical company's stock valued at $70,757,000 after acquiring an additional 16,440 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Celldex Therapeutics by 23.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,557,136 shares of the biopharmaceutical company's stock valued at $89,890,000 after acquiring an additional 676,771 shares during the last quarter. Point72 Asset Management L.P. raised its position in shares of Celldex Therapeutics by 50.8% during the 4th quarter. Point72 Asset Management L.P. now owns 2,515,972 shares of the biopharmaceutical company's stock valued at $63,579,000 after acquiring an additional 847,264 shares during the last quarter. Deep Track Capital LP bought a new stake in shares of Celldex Therapeutics during the 4th quarter valued at $38,919,000. Finally, Novo Holdings A S raised its position in shares of Celldex Therapeutics by 3.8% during the 4th quarter. Novo Holdings A S now owns 1,000,000 shares of the biopharmaceutical company's stock valued at $25,270,000 after acquiring an additional 36,337 shares during the last quarter.

Analysts Set New Price Targets

A number of analysts recently commented on CLDX shares. UBS Group lowered their price objective on shares of Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Morgan Stanley lowered their price objective on shares of Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. Canaccord Genuity Group lowered their price objective on shares of Celldex Therapeutics from $64.00 to $62.00 and set a "buy" rating for the company in a research report on Wednesday. The Goldman Sachs Group lowered their price objective on shares of Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. Finally, HC Wainwright lowered their price objective on shares of Celldex Therapeutics from $50.00 to $42.00 and set a "buy" rating for the company in a research report on Wednesday. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $46.67.

Celldex Therapeutics Price Performance

CLDX stock traded up $0.44 during trading hours on Friday, reaching $22.46. 1,797,765 shares of the stock were exchanged, compared to its average volume of 1,313,527. The firm's 50-day moving average is $22.12 and its 200-day moving average is $20.64. The company has a market cap of $1.49 billion, a price-to-earnings ratio of -7.46 and a beta of 1.22. Celldex Therapeutics, Inc. has a 12 month low of $14.40 and a 12 month high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.86) by $0.01. The firm had revenue of $0.73 million during the quarter, compared to analysts' expectations of $1.13 million. Celldex Therapeutics had a negative return on equity of 27.61% and a negative net margin of 3,446.88%. As a group, equities research analysts forecast that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.